GERN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GE

Mkt Cap

$754.9M

Volume

3.24M

Next Earnings

November 4th

Loading chart

GE

GERNGeron Corp

GERN

Pay with—

Available Balance0.00

GE

Mkt Cap

$790.2M

Volume

3.24M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Bristol Myers is relying on its growth portfolio including Reblozyl, Opdivo, and other key drugs to drive top-line growth as legacy drug sales decline. Reblozyl sales reached nearly $1.3 billion in H1 2026, up 23% year-over-year, with potential for further growth from new indications. However, the company faces increasing competition from Geron's Rytelo and Keros Therapeutics' elritercept in the MDS and myelofibrosis treatment space.Zacks Investment Research · Oct 7, 2026

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.Benzinga · May 20, 2026

Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026Geron Corporation announced it will release its first quarter 2026 financial results on May 6, 2026, followed by a conference call and webcast at 8:00 a.m. Eastern Time. The commercial-stage biopharmaceutical company continues to advance its telomerase inhibitor RYTELO® (imetelstat), which is approved in the U.S. and EU for treating lower-risk myelodysplastic syndromes, and is conducting a Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis.GlobeNewswire Inc. · Apr 22, 2026

Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate SecretaryGeron Corporation announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. Williams brings extensive biopharmaceutical industry experience from previous roles at Vanda Pharmaceuticals, AgNovos Bioscience, and Stryker Corporation. The appointment is part of recent leadership strengthening efforts at the commercial-stage blood cancer treatment company.GlobeNewswire Inc. · Apr 13, 2026

Geron to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGeron Corporation announced that its management team will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The commercial-stage biopharmaceutical company, which markets RYTELO® (imetelstat) for treating lower-risk myelodysplastic syndromes, continues to conduct pivotal Phase 3 trials in JAK-inhibitor relapsed/refractory myelofibrosis and other hematologic malignancies.GlobeNewswire Inc. · Apr 6, 2026

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsGeron Corporation reported full year 2025 RYTELO net product revenue of $184 million with Q4 revenue of $48 million. The company ended 2025 with $401 million in cash and expects 2026 RYTELO revenue between $220-240 million. Operating expenses totaled $255 million in 2025, within guidance. Geron implemented a workforce reduction of approximately one-third in December 2025 and reiterated focus on driving U.S. commercial growth while pursuing international expansion opportunities.GlobeNewswire Inc. · Feb 25, 2026

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value CreationGeron Corporation plans to reduce workforce by one-third and streamline operations to improve financial discipline, focusing on RYTELO commercial growth and clinical development while reducing 2026 operating expenses.GlobeNewswire Inc. · Dec 11, 2025

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsMultiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.Benzinga · Dec 4, 2025

GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmLaw firm investigating potential claims against Geron Corporation regarding alleged misleading statements about drug Rytelo's launch and growth potential during February 2024-2025 period.GlobeNewswire Inc. · Oct 23, 2025

Cassava Sciences Appoints Dawn C. Bir to the Board of DirectorsBiotechnology company Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors, bringing extensive biopharmaceutical executive experience to support the company's clinical development of simufilam for TSC-related epilepsy.GlobeNewswire Inc. · Oct 22, 2025

to start trading

GE

GERNGeron Corp

GERN

Pay with—

Available Balance0.00

Your PositionYou don't own any GERN yet.

Related Tickers

Earnings